DMAC (DiaMedica Therapeutics) Other Income (Expense): $1.72 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMAC DiaMedica Therapeutics Inc DMAC
29 GF Score
Price $6.63
! 2 Warning Signs
View Full Analysis

What is DiaMedica Therapeutics Other Income (Expense)?

DiaMedica Therapeutics DMAC +1.38% 29 Other Income (Expense) is $1.72 Mil as of Jun. 2026. GuruFocus rates DMAC with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

DiaMedica Therapeutics's other income expense for the DiaMedica Therapeutics's pretax income for the three months ended in Jun. 2026 was $0.37 Mil. Its other income expense for the trailing twelve months (TTM) ended in Jun. 2026 was $1.72 Mil.

DiaMedica Therapeutics  (NAS:DMAC) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

DiaMedica Therapeutics Other Income (Expense) Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics Other Income (Expense) Chart

DiaMedica Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.35 1.93 -0.03 -0.01

DiaMedica Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.42 0.01 0.45 0.37
DMAC
29GF Score
DiaMedica Therapeutics Inc DMAC
Other Income (Expense) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DiaMedica Therapeutics Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Income (Expense) →
What does a Other Income (Expense) of $1.72 Mil mean?
DiaMedica Therapeutics (DMAC) has a Other Income (Expense) of $1.72 Mil as of Jun. 2026. Other income and expenses that a company records on the income statement. View historical data on DiaMedica Therapeutics and its competitors.
Is DiaMedica Therapeutics' Other Income (Expense) too high?
DiaMedica Therapeutics' current Other Income (Expense) is $1.72 Mil. Overall, DiaMedica Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Other Income (Expense) compare to SABS and AGEN?
DiaMedica Therapeutics' Other Income (Expense) of $1.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Income (Expense) for a Biotechnology company?
A good Other Income (Expense) depends on the Biotechnology industry context. However, Other Income (Expense) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Income (Expense) mean?
A high Other Income (Expense) can signal that a stock is expensive relative to its fundamentals. Other income and expenses that a company records on the income statement. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current Other Income (Expense) is $1.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Other Income (Expense) of $1.72 Mil. The current Other Income (Expense) is $1.72 Mil. DiaMedica Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Income (Expense) calculated?
Other Income (Expense) is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Other Income (Expense) is $1.72 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
29GF Score

Get the complete analysis for DMAC

Other Income (Expense) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.63
Price